MTG1

Across TCGA pan-cancer cohorts, MTG1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTG1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MTG1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MTG1 expression acts as an unfavorable survival marker, although some lineages such as OV and PDAC show a favorable association.

HNSC, OV, and PDAC are the cancer types where MTG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.809	0.911	.025	6	view →
OV	DFS	Median	All	0.935	0.648	.036	4	view →
PDAC	OS	Median	All	0.553	0.317	.009	3	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.861	.023	2	view →
GBM	OS	Quartile	All	0.792	0.538	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTG1–HNSC (OS)

Open the HNSC breakdown →